Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis

References

• Sarbu M-I, Mitran M-I, Mitran C-I, et al. The pathophysiological mechanisms and the quest for biomarkers in psoriasis, a stress-related skin disease. Dis Markers. 2018;2018:5823684.
   PubMed Web of Science ®Google Scholar
• Jansen PA, Rodijk-Olthuis D, Hollox EJ, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One. 2009;4(3):e4725.
   PubMed Web of Science ®Google Scholar
• Shahidi-Dadras M, Abdollahimajd F, Younespour S, et al. Serum vascular endothelial growth factor in Iranian patients with moderate-severe psoriasis before and after treatment: a PASI-75 response as a practical treatment goal. Iranian J Dermatol. 2016;19(4):119–124.
   Google Scholar
• Shahidi‐Dadras M, Haghighatkhah HR, Abdollahimajd F, et al. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis. Int J Dermatol. 2016;55(1):52–59.
   PubMed Web of Science ®Google Scholar
• Wang D, Fang L, Pan G. Association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis: an updated meta-analysis. Dis Markers. 2019;2019:7361826.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhang S, Su X, et al. Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis. Postgrad Med. 2019;131(6):405–412.
   PubMedGoogle Scholar
• Niknezhad N, Haghighatkhah HR, Zargari O, et al. High‐sensitivity C‐reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther. 2020;33(4):e13628.
   PubMed Web of Science ®Google Scholar
• Joshi AA, Lerman JB, Aberra TM, et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016;119(11):1242–1253.
   PubMed Web of Science ®Google Scholar
• Awad S, Attallah D, Salama R, et al. Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis. Clin Exp Dermatol. 2018;43(3):262–267.
   PubMed Web of Science ®Google Scholar
• Forouzandeh M, Besen J, Keane RW, et al. The inflammasome signaling proteins ASC and IL-18 as biomarkers of psoriasis. Front Pharmacol. 2020;11:1238.
   PubMed Web of Science ®Google Scholar
• Robati RM, Partovi-Kia M, Haghighatkhah HR, et al. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis? J Am Acad Dermatol. 2014;71(4):642–648.
   PubMed Web of Science ®Google Scholar
• Abji F, Pollock RA, Liang K, et al. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 2016;68(12):2911–2916.
   PubMed Web of Science ®Google Scholar
• Mahendran SM, Chandran V. Exploring the psoriatic arthritis proteome in search of novel biomarkers. Proteomes. 2018;6(1):5.
   PubMed Web of Science ®Google Scholar
• Wade SM, McGarry T, Wade SC, et al. Serum microRNA signature as a diagnostic and therapeutic marker in patients with psoriatic arthritis. J Rheumatol. 2020;47(12):1760–1767.
   PubMed Web of Science ®Google Scholar
• Jadon DR, Stober C, Pennington SR, et al. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. 2020;16(11):609–627.
   PubMed Web of Science ®Google Scholar
• Sanz-Martínez MT, Moga E, Martínez MAS, et al. High levels of platelet-lymphocyte complexes in patients with psoriasis are associated with a better response to anti-TNF-α therapy. J Invest Dermatol. 2020;140(6):1176–1183.
   PubMed Web of Science ®Google Scholar
• Pouw J, Leijten E, Radstake T, et al. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature. Clin Immunol. 2020;211:108318.
   PubMed Web of Science ®Google Scholar
• Shibuya T, Honma M, Iinuma S, et al. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: possibility as a marker reflecting favorable response to anti-interleukin-17A agents. J Dermatol. 2018;45(6):710–714.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Kamata M, Shimizu T, et al. Thymus and activation-regulated chemokine (TARC) in patients with psoriasis: increased serum TARC levels in patients with generalized pustular psoriasis. J Dermatol. 2020;47(10):1149–1156.
   PubMed Web of Science ®Google Scholar
• Najar Nobari N, Shahidi Dadras M, Nasiri S, et al. Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF‐α inhibitors in psoriatic patients. Dermatol Ther. 2020;33(4):e13457.
   PubMed Web of Science ®Google Scholar
• Maybury C, Samarasekera E, Douiri A, et al. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. Br J Dermatol. 2014;170(6):1237–1247.
   PubMed Web of Science ®Google Scholar
• Martyn‐Simmons C, Rosenberg W, Cross R, et al. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Br J Dermatol. 2014;171(2):267–273.
   PubMed Web of Science ®Google Scholar
• Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med (Lond). 2018;79(12):694–699.
   PubMed Web of Science ®Google Scholar
• Hassab‐El‐Naby HM, Helal EA, Abdou AM, et al. Evaluation of tissue and serum lipocalin 2 in psoriasis vulgaris and its implications on subclinical atherosclerosis. Dermatol Rev. 2021;2(5):245–250.
   Google Scholar
• Khashaba SA, Attwa E, Said N, et al. Serum YKL-40 and IL 17 in psoriasis: reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatol Ther. 2021;34(1):e14606.
   PubMed Web of Science ®Google Scholar
• Sokolova MV, Simon D, Nas K, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):26.
   PubMed Web of Science ®Google Scholar
• Bai F, Zheng W, Dong Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9(1):1266–1278.
   PubMedGoogle Scholar
• Teixeira GG, Mari NL, de Paula JCC, et al. Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis. Clin Exp Med. 2020;20(1):39–48.
   PubMed Web of Science ®Google Scholar
• Zdanowska N, Owczarczyk-Saczonek A, Czerwińska J, et al. Methotrexate and adalimumab decrease the serum levels of cardiovascular disease biomarkers (VCAM-1 and E-Selectin) in plaque psoriasis. Medicina. 2020;56(9):473.
   PubMedGoogle Scholar
• Generali E, Scirè CA, Favalli EG, et al. Biomarkers in psoriatic arthritis: a systematic literature review. Expert Rev Clin Immunol. 2016;12(6):651–660.
   PubMed Web of Science ®Google Scholar
• Boyd T, Eastman P, Huynh D, et al. Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. Expert Rev Clin Immunol. 2020;16(3):335–341.
   PubMed Web of Science ®Google Scholar
• Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii104–ii110.
   PubMedGoogle Scholar
• Cretu D, Gao L, Liang K, et al. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res (Hoboken). 2018;70(3):454–461.
   PubMed Web of Science ®Google Scholar
• Waszczykowski M, Bednarski I, Narbutt J, et al. Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage. Postepy Dermatol Alergol. 2020;37(6):1001–1008.
   PubMed Web of Science ®Google Scholar
• Chandran V. Pathway to biomarker discovery in psoriatic arthritis. Expert Rev Clin Immunol. 2020;16(5):471–478.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Barton A, for OUTPASS. Association of pharmacological biomarkers with treatment response and longterm disability in patients with psoriatic arthritis: results from OUTPASS. J Rheumatol. 2020;47(8):1204–1208.
   PubMed Web of Science ®Google Scholar
• Morita A, Tani Y, Matsumoto K, et al. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020;47(5):452–457.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wu DH, Han L, et al. Roles of microRNAs in psoriasis: immunological functions and potential biomarkers. Exp Dermatol. 2017;26(4):359–367.
   PubMed Web of Science ®Google Scholar
• Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis: an observational cohort study. Circ Res. 2018;123(11):1244–1254.
   PubMed Web of Science ®Google Scholar
• Kanelleas A, Liapi C, Katoulis A, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol: Clin Dermatol. 2011;36(8):845–850.
   PubMed Web of Science ®Google Scholar
• Siegel D, Devaraj S, Mitra A, et al. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol. 2013;44(2):194–204.
   PubMed Web of Science ®Google Scholar
• Horn CS, Ilg R, Sander K, et al. High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. J Neurol. 2009;256(5):783–791.
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29(8):439–493.
   PubMed Web of Science ®Google Scholar
• Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71(1):92–100.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Shalaurova I, Wolak-Dinsmore J, et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714–723.
   PubMed Web of Science ®Google Scholar
• Hegyi Z, Zwicker S, Bureik D, et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132(5):1416–1424.
   PubMed Web of Science ®Google Scholar
• Enerblsquäck C. Soluble biomarkers in psoriasis. Eur J Dermatol. 2012;21(6):844–850.
   Web of Science ®Google Scholar
• Turina MC, Landewé R, Baeten D. Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. Expert Rev Clin Immunol. 2017;13(4):333–344.
   PubMed Web of Science ®Google Scholar
• Abed I. Psoriasis: tumor necrosis factor–α, interleukin 18, C reactive protein polymorphism, and osteopontin role. IJMS. 2018;1(1):58–62.
   Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology. 2017;233(5):378–389.
   PubMed Web of Science ®Google Scholar
• Kaur S, Kingo K, Zilmer M. Psoriasis and cardiovascular risk-do promising new biomarkers have clinical impact? Mediators Inflamm. 2017;2017:7279818.
   PubMed Web of Science ®Google Scholar
• Sobchak C, Eder L. Cardiometabolic disorders in psoriatic disease. Curr Rheumatol Rep. 2017;19(10):63–68.
   PubMed Web of Science ®Google Scholar
• Cataldi C, Mari NL, Lozovoy MAB, et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res. 2019;68(7):557–567.
   PubMed Web of Science ®Google Scholar
• Shahidi‐Dadras M, Niknezhad N, Niknejad N, et al. Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease? Dermatol Ther. 2019;32(3):e12865.
   PubMed Web of Science ®Google Scholar
• Abdollahimajd F, Niknezhad N, Haghighatkhah HR, et al. Angiotensin-converting enzyme and subclinical atherosclerosis in psoriasis: is there any association? A case-control study. J Am Acad Dermatol. 2020;82(4):980–981.e1.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Cerdeira C, Cordeiro-Rodríguez M, Carnero-Gregorio M, et al. Biomarkers of inflammation in obesity-psoriatic patients. Mediators Inflamm. 2019;2019:7353420.
   PubMed Web of Science ®Google Scholar
• Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–166.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152–2154.
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–1050.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13(3):272–280.
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130.
   PubMed Web of Science ®Google Scholar
• Barker J, Horn E, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25(7):758–764.
   PubMed Web of Science ®Google Scholar
• Van Der Voort E, Nijsten T. Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic arthritis and rheumatoid arthritis patients: a daily practice comparison with procollagen-3 N-terminal peptide (P3NP): P011. J Eur Acad Dermatol Venereol. 2016;30.
   Web of Science ®Google Scholar
• Wang Z, Huang Y, Nossent H, et al. Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: a retrospective cohort study. JGH Open. 2020;4(6):1211–1216.
   PubMed Web of Science ®Google Scholar
• Chládek J, S˘Imková M, Vanec˘Ková J, et al. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol Venereol. 2013;27(8):1007–1014.
   PubMed Web of Science ®Google Scholar
• Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol. 2014;150(8):856–862.
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Nadeem A, Ansari MA, et al. Psoriasis-like inflammation leads to renal dysfunction via upregulation of NADPH oxidases and inducible nitric oxide synthase. Int Immunopharmacol. 2017;46:1–8.
   PubMed Web of Science ®Google Scholar
• Ren F, Zhang M, Zhang C, et al. Psoriasis-like inflammation induced renal dysfunction through the TLR/NF-κB signal pathway. BioMed Res Int. 2020;2020:3535264.
   PubMed Web of Science ®Google Scholar
• Nicolae I, Ene CD, Mitran CI, et al. Correlations between related-purine derivatives and renal disorders in patients with psoriasis vulgaris. Exp Ther Med. 2019;17(2):1012–1019.
   PubMed Web of Science ®Google Scholar